Managers / Q4 2022 · view latest →
Birchview Capital, LP
CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826
Reported Value
Under review
reported total failed a data-quality check
Positions
57
Filings on Record
39
2019–present window
Filed
Feb 3, 2023
original filing
Summary
Compared with Q3 2022, the fund opened 3 new positions and exited 6.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 82.9% · $117,389
- Other · 17.1% · $24,177
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| HALOHALOZYME THERAPEUTICS INC | NEW | +10.0K | 10.0K | +$569 | $569 |
| TXG10X GENOMICS INC | NEW | +10.0K | 10.0K | +$364 | $364 |
| KROSKEROS THERAPEUTICS INC | NEW | +7.0K | 7.0K | +$336 | $336 |
| ATECALPHATEC HOLDINGS INC | ADDED | +80.0K | 90.0K | −$85,888 | $1,112 |
| BIODESIX INC | ADDED | +2.67M | 5.04M | −$3M | $11,591 |
| CLRUSDCONTINENTAL RESOURCES INC | SOLD OUT | −38.6K | 0 | −$3M | $0 |
| CCXIEURCHEMOCENTRYX INC | SOLD OUT | −20.0K | 0 | −$1M | $0 |
| INARI MEDICAL INC | SOLD OUT | −10.0K | 0 | −$726,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
50 positions
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $176M | 73 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $171M | 68 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $132M | 69 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $101M | 71 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $115M | 68 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $123M | 68 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $115M | 62 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $108M | 61 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $122M | 60 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $128M | 59 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $117M | 52 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | Under review | 54 | Aug 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $127,725 | 55 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 57 | Feb 3, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $142M | 60 | Nov 28, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2022 | $137M | 64 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $139M | 63 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $155M | 67 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $147M | 64 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $167M | 62 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $168M | 54 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $174M | 48 | Feb 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $150M | 50 | Nov 12, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $165M | 51 | Aug 10, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $113M | 46 | May 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $138M | 52 | Feb 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $150M | 50 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $164M | 54 | Aug 6, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $160M | 54 | May 3, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $106M | 52 | Feb 6, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.